Drug Development/R&D

What will drug development look like in 10 years’ time? How will regulatory policies and the global political and social environment shape it? How might policy choices affect the rate and direction of R&D? Which initiatives might help ensure that the UK will continue to host important R&D? These and other critical questions will be addressed at OHE’s 50th Anniversary conference.

OHE has added important panelists and speakers to fill out the conference programme for The Challenges and Economics of Drug Development in 2022, scheduled for 8 October in London. The conference, which celebrates OHE’s 50th anniversary, will explore current and emerging critical changes in the science, organisation and economics of drug discovery and development.

Throughout its 50-year history, OHE has been a leader in contributing to the understanding of important trends in health care and in the life science industries, in the UK and outside. This conference, which celebrates OHE’s 50th anniversary, will explore current and emerging critical changes in the science, organisation and economics of drug discovery and development.

In response to the R&D productivity crisis affecting the pharmaceutical industry, "big pharma" is seeking to source therapeutics from small and medium sized enterprises (SMEs). In this seminar, Dr Michael Hopkins of the University of Sussex will discuss his research tracking the SMEs that have played a part in projects reaching late stage clinical trials.

The Economics of Drug Development in 2022 On 8 October, 2012, in celebration of its 50th anniversary, OHE will be holding an important conference to consider what drug development may look like ten years hence, in 2022. The conference will be held in London on Monday, 8 October 2012.

In response to the R&D productivity crisis affecting the pharmaceutical industry, "big pharma" is seeking to source therapeutics from small and medium sized enterprises (SMEs). In this seminar, Dr Michael Hopkins of the University of Sussex will discuss his research tracking the SMEs that have played a part in projects reaching late stage clinical trials.

Now available from the OHE website, this report provides a clear explanation of the complex nature of innovation in medicines. A fully revised and expanded version of the 2005 edition of The Many Faces of Innovation, it updates the review of the literature on the economics of innovation, traces important innovation that has occurred since the earlier report, adds new case studies, and updates the discussion of competition in pharmaceutical R&D.

OHE’s Adrian Towse is co-author on the recent report by the ISPOR Good Research Practices Task Force on assessing comparative effectiveness using prospective observational studies.

Just published are the results of an OHE Lunchtime Seminar given by Prof Riccaboni, from the University of Trento. In this publication, he explores whether R&D productivity in the pharmaceutical industry has declined and, if so, why.

Every year, OHE sponsors a lecture by an eminent economist or clinician that addresses an important current issue.

Pages

Subscribe to RSS - Drug Development/R&D